Evidence map›Paper›PMID 38473294›Full record

ArticleCancers2024

Incidence and Mortality of Uveal Melanoma in Hungary: A Nationwide Study.

Gábor Tóth, Béla Muzsik, Attila Szajkó, Pál Kerber, Elek Dinya, Béla Csákány, Zoltán Zsolt Nagy, János Németh

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Gábor TóthDepartment of Ophthalmology, Semmelweis University, Mária utca 39, H-1085 Budapest, Hungary.ORCID 0000-0002-9176-9442
Béla MuzsikNational Directorate General for Hospitals, Diós árok 3, H-1125 Budapest, Hungary.ORCID 0009-0004-9141-1573
Attila SzajkóNational Directorate General for Hospitals, Diós árok 3, H-1125 Budapest, Hungary.
Pál KerberNational Directorate General for Hospitals, Diós árok 3, H-1125 Budapest, Hungary.
Elek DinyaInstitute of Digital Health Sciences, Semmelweis University, Ferenc tér 15, H-1094 Budapest, Hungary.
Béla CsákányDepartment of Ophthalmology, Semmelweis University, Mária utca 39, H-1085 Budapest, Hungary.
Zoltán Zsolt NagyDepartment of Ophthalmology, Semmelweis University, Mária utca 39, H-1085 Budapest, Hungary.
János NémethDepartment of Ophthalmology, Semmelweis University, Mária utca 39, H-1085 Budapest, Hungary.ORCID 0000-0001-8575-4888
Semmelweis University · HUNational Healthcare Service Center · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uveal melanoma (UM) is the most common primary malignant ocular tumour in adults, although its epidemiology in Central and Eastern Europe is unclear. This study aimed to analyse the incidence and all-cause mortality of UM in Hungary. This nationwide, retrospective, longitudinal study used data from the National Health Insurance Fund and included patients aged ≥18 years who were newly diagnosed with UM (ICD-10 C69.3 or C69.4) between 1 January 2012 and 31 December 2021. Age-standardised incidence and all-cause mortality rates were calculated using European Standard Population data from 2013. We identified 88 and 70 new patients with UM in 2012 and 2021, respectively, showing an almost stable trend. Age-standardised incidence rates varied between 6.40 and 10.96/1,000,000 person-years (PYs) during the analysed period. The highest age-standardised incidence was detected among men (13.38/1,000,000 PYs) in 2015. All-cause mortality decreased from 4.72/1,000,000 PYs to 0.79/1,000,000 PYs between 2012 and 2021. In conclusion, the UM incidence rate in Hungary is comparable to European incidence rates. The incidence did not markedly change, whereas all-cause mortality decreased during the study period, but this decline could not be attributed to improved treatment modalities for primary tumours and metastatic UM.

Indexed as

Central and Eastern EuropeHungaryincidencemortalityuveal melanoma

Identifiers

PMID38473294
PMCPMC10931129
OpenAlexW4392169716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.